Stonington, CT, United States of America

Spiros Liras

This inventor holds 18 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 2 EPO patents. Top assignees: Pfizer Corporation, Neurogen Corporation, Migenix, Inc.. Active years: 2002-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Spiros Liras. Retrieved from https://idiyas.com/inventor/spiros-liras

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 1)

% Patents Active = 50.0

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 3.2

ph-index = 8

Forward Citations = 149(Granted Patents)

Location History:

Stonington, CT (US) (2002 - 2010)
Brookline, MA (US) (2016 - 2020)

Company Filing History:

University of California

patents

5. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2020

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10851367 - Tissue-specific genome engineering using CRISPR-Cas9 (2020-12-01),

2. 10813942 - Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR (2020-10-27),

3. 10376531 - Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR (2019-08-13),

4. 10039778 - Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR (2018-08-07),

5. 9617293 - Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR (2017-04-11),

6. 9340553 - Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR (2016-05-17),

7. 7642267 - Benzimidazole and pyridylimidazole derivatives (2010-01-05),

8. 7521464 - Pyrazole compounds for treatment of neurodegenerative disorders (2009-04-21),

9. 7456177 - Heteroaryl fused azapolycyclic compounds (2008-11-25),

10. 7300945 - Benzimidazole and pyridylimidazole derivatives (2007-11-27),

11. 7268142 - Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline (2007-09-11),

12. 7238721 - Pyrazole compounds for treatment of neurodegenerative disorders (2007-07-03),

13. 7049335 - 3-azabicyclo[3.1.0]hexane derivatives (2006-05-23),

14. 6936638 - Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto (2005-08-30),

15. 6720336 - 4,4-biarylpiperidine derivatives (2004-04-13),

Title: Spotlight on Inventor Spiros Liras

Introduction:

Meet Spiros Liras, a prolific inventor hailing from Stonington, CT (US). With an impressive portfolio of 18 patents under his belt, Spiros is making waves in the field of innovation and research.

Latest Patents:

Spiros Liras' latest patents showcase his cutting-edge work in tissue-specific genome engineering using CRISPR-Cas9. These patents provide compounds and compositions for treating various diseases, conditions, and disorders, as well as serving as asialoglycoprotein receptor (ASGPR) targeting agents. Additionally, his work on Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds demonstrates their potential as targeting agents for ASGPR and in the treatment of related ailments.

Career Highlights:

Throughout his career, Spiros Liras has lent his expertise to renowned companies such as Pfizer Corporation and Neurogen Corporation. His innovative spirit and dedication to advancing medical research have significantly contributed to the pharmaceutical industry's progress.

Collaborations:

Spiros has collaborated with esteemed professionals in the field, including Martin Patrick Allen and Vincent Mascitti. Together, they have worked on groundbreaking projects that have the potential to revolutionize healthcare and treatment methodologies.

Conclusion:

Inventor Spiros Liras stands as a beacon of innovation, leaving an indelible mark on the world of research and development. His commitment to pushing the boundaries of science and medicine underscores his invaluable contributions to the field.

Profile summary based on public USPTO records.